Loading...
•
Dec 31, 2019
Matinas BioPharma Q4 2019 Earnings Report
Reported fourth quarter and full year 2019 financial results and operational highlights.
Key Takeaways
Matinas BioPharma reported a net loss attributable to common shareholders of $5.8 million for the fourth quarter of 2019. The company's cash, cash equivalents and marketable securities were approximately $27.8 million as of December 31, 2019. They initiated the ENHANCE-IT study of MAT9001 against Vascepa and the efficacy phase of the NIH-funded EnACT study of MAT2203.
Initiated ENHANCE-IT study of MAT9001 against Vascepa, with topline data expected in Q4 2020.
Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis in Q1 2020.
Cash, cash equivalents and marketable securities were approximately $27.8 million at December 31, 2019.
Net loss attributable to common shareholders was $5.8 million, or a net loss per share of $0.04 for the fourth quarter of 2019.
Forward Guidance
Matinas BioPharma believes that cash on hand is sufficient to fund operations into the second half of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...